J. Miller and W. Wynn, A malignant tumour arising from the endothelium of the peritoneum, and producing a mucoid ascitic fluid, The Journal of Pathology and Bacteriology, vol.xli, issue.2, pp.267-78, 1908.
DOI : 10.1002/path.1700120212

J. Wagner, Asbestos cancers, J Natl Cancer Inst, vol.46, pp.5-9, 1971.

P. Boffetta, Epidemiology of peritoneal mesothelioma: a review, Annals of Oncology, vol.18, issue.6, pp.985-90, 2007.
DOI : 10.1093/annonc/mdl345

K. Antman, K. Klegar, E. Pomfret, R. Osteen, D. Amato et al., EARLY PERITONEAL MESOTHELIOMA: A TREATABLE MALIGNANCY, The Lancet, vol.326, issue.8462, pp.977-81, 1985.
DOI : 10.1016/S0140-6736(85)90526-4

B. Robinson and R. Lake, Advances in Malignant Mesothelioma, New England Journal of Medicine, vol.353, issue.15, pp.1591-603, 2005.
DOI : 10.1056/NEJMra050152

V. Manzini, L. Recchia, M. Cafferata, C. Porta, S. Siena et al., Malignant peritoneal mesothelioma: a multicenter study on 81 cases, Annals of Oncology, vol.21, issue.2, pp.348-53, 2010.
DOI : 10.1093/annonc/mdp307

K. Antman, R. Blum, J. Greenberger, G. Flowerdew, A. Skarin et al., Multimodality therapy for malignant mesothelioma based on a study of natural history, The American Journal of Medicine, vol.68, issue.3, pp.356-62, 1980.
DOI : 10.1016/0002-9343(80)90103-5

G. Carteni, C. Manegold, G. Garcia, S. Siena, C. Zielinski et al., Malignant peritoneal mesothelioma???Results from the International Expanded Access Program using pemetrexed alone or in combination with a platinum agent, Lung Cancer, vol.64, issue.2, pp.211-219, 2009.
DOI : 10.1016/j.lungcan.2008.08.013

P. Jä-nne, A. Wozniak, C. Belani, M. Keohan, H. Ross et al., Open-Label Study of Pemetrexed Alone or in Combination with Cisplatin for the Treatment of Patients with Peritoneal Mesothelioma: Outcomes of an Expanded Access Program, Clinical Lung Cancer, vol.7, issue.1, pp.40-46, 2005.
DOI : 10.3816/CLC.2005.n.020

R. Garcia-carbonero and L. Paz-ares, Systemic chemotherapy in the management of malignant peritoneal mesothelioma, European Journal of Surgical Oncology (EJSO), vol.32, issue.6, pp.676-81, 2006.
DOI : 10.1016/j.ejso.2006.03.009

M. Tattersall, R. Fox, E. Newlands, and R. Woods, INTRACAVITARY DOXORUBICIN IN MALIGNANT EFFUSIONS, The Lancet, vol.313, issue.8112, p.390, 1979.
DOI : 10.1016/S0140-6736(79)92937-4

E. Rogoff, B. Hilaris, and A. Huvos, Long-term survival in patients with malignant peritoneal mesothelioma treated with irradiation, Cancer, vol.13, issue.3, pp.656-64, 1973.
DOI : 10.1002/1097-0142(197309)32:3<656::AID-CNCR2820320319>3.0.CO;2-U

T. Yan, M. Deraco, D. Baratti, S. Kusamura, D. Elias et al., Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Malignant Peritoneal Mesothelioma: Multi-Institutional Experience, Journal of Clinical Oncology, vol.27, issue.36, pp.6237-6279, 2009.
DOI : 10.1200/JCO.2009.23.9640

D. Baratti, S. Kusamura, A. Cabras, R. Bertulli, I. Hutanu et al., Diffuse malignant peritoneal mesothelioma: Long-term survival with complete cytoreductive surgery followed by hyperthermic intraperitoneal chemotherapy (HIPEC), European Journal of Cancer, vol.49, issue.15, pp.3140-3148, 2013.
DOI : 10.1016/j.ejca.2013.05.027

A. Husain, T. Colby, N. Ordó-n-?-ez, T. Krausz, A. Borczuk et al., Guidelines for pathologic diagnosis of malignant mesothelioma: a consensus statement from the International Mesothelioma Interest Group, Arch Pathol Lab Med, vol.133, pp.1317-1348, 2009.

A. Husain, T. Colby, N. Ordonez, T. Krausz, R. Attanoos et al., Guidelines for Pathologic Diagnosis of Malignant Mesothelioma: 2012 Update of the Consensus Statement from the International Mesothelioma Interest Group, Archives of Pathology & Laboratory Medicine, vol.137, issue.5, pp.647-67, 2013.
DOI : 10.5858/arpa.2012-0214-OA

D. Baratti, S. Kusamura, D. Nonaka, G. Oliva, B. Laterza et al., Multicystic and Well-differentiated Papillary Peritoneal Mesothelioma Treated by Surgical Cytoreduction and Hyperthermic Intra-peritoneal Chemotherapy (HIPEC), Annals of Surgical Oncology, vol.417, issue.10, pp.2790-2797, 2007.
DOI : 10.1245/s10434-007-9475-8

T. Yan, M. Deraco, D. Elias, O. Glehen, E. Levine et al., A novel tumor-node-metastasis (TNM) staging system of diffuse malignant peritoneal mesothelioma using outcome analysis of a multi-institutional database*, Cancer, vol.17, issue.9, pp.1855-63, 2010.
DOI : 10.1002/cncr.25640

P. Mirarabshahii, K. Pillai, T. Chua, M. Pourgholami, and D. Morris, Diffuse malignant peritoneal mesothelioma ??? An update on treatment, Cancer Treatment Reviews, vol.38, issue.6, pp.605-617, 2012.
DOI : 10.1016/j.ctrv.2011.10.006

G. Simon, C. Verschraegen, P. Janne, C. Langer, A. Dowlati et al., Pemetrexed Plus Gemcitabine As First-Line Chemotherapy for Patients With Peritoneal Mesothelioma: Final Report of a Phase II Trial, Journal of Clinical Oncology, vol.26, issue.21, pp.3567-72, 2008.
DOI : 10.1200/JCO.2007.15.2868

M. Deraco, D. Baratti, I. Hutanu, R. Bertuli, and S. Kusamura, The Role of Perioperative Systemic Chemotherapy in Diffuse Malignant Peritoneal Mesothelioma Patients Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy, Annals of Surgical Oncology, vol.46, issue.4, pp.1093-100, 2013.
DOI : 10.1245/s10434-012-2845-x

L. Villeneuve, S. Isaac, O. Glehen, M. Capovilla, A. Chevallier et al., R??seau RENAPE??: vers une nouvelle organisation des soins pour le traitement des tumeurs rares du p??ritoine. Description du r??seau et r??le des pathologistes, Annales de Pathologie, vol.34, issue.1, pp.4-8, 2014.
DOI : 10.1016/j.annpat.2014.01.008

M. Oken, R. Creech, D. Tormey, J. Horton, T. Davis et al., Toxicity and response criteria of the Eastern Cooperative Oncology Group, AMERICAN JOURNAL OF CLINICAL ONCOLOGY, vol.5, issue.6, pp.649-55, 1982.
DOI : 10.1097/00000421-198212000-00014

P. Jacquet and P. Sugarbaker, Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis, Cancer Treat Res, vol.82, pp.359-74, 1996.
DOI : 10.1007/978-1-4613-1247-5_23

P. Sugarbaker, Peritonectomy procedures, Surgical Oncology Clinics of North America, vol.12, issue.3, pp.29-42, 1995.
DOI : 10.1016/S1055-3207(03)00048-6

E. Cotte, G. Passot, F. Gilly, and O. Glehen, Selection of patients and staging of peritoneal surface malignancies, World Journal of Gastrointestinal Oncology, vol.2, issue.1, pp.31-36, 2010.
DOI : 10.4251/wjgo.v2.i1.31

T. Berghmans, M. Paesmans, Y. Lalami, I. Louviaux, S. Luce et al., Activity of chemotherapy and immunotherapy on malignant mesothelioma: a systematic review of the literature with meta-analysis, Lung Cancer, vol.38, issue.2, pp.111-132, 2002.
DOI : 10.1016/S0169-5002(02)00180-0

A. Feldman, S. Libutti, J. Pingpank, D. Barlett, T. Beresnev et al., Analysis of Factors Associated With Outcome in Patients With Malignant Peritoneal Mesothelioma Undergoing Surgical Debulking and Intraperitoneal Chemotherapy, Journal of Clinical Oncology, vol.21, issue.24, pp.4560-4567, 2003.
DOI : 10.1200/JCO.2003.04.150

P. Sugarbaker, T. Yan, O. Stuart, and D. Yoo, Comprehensive management of diffuse malignant peritoneal mesothelioma, European Journal of Surgical Oncology (EJSO), vol.32, issue.6, pp.686-91, 2006.
DOI : 10.1016/j.ejso.2006.03.012

T. Yan, E. Brun, C. Cerruto, N. Haveric, D. Chang et al., Prognostic indicators for patients undergoing cytoreductive surgery and perioperative intraperitoneal chemotherapy for diffuse malignant peritoneal mesotheliomay

D. Baratti, S. Kusamura, A. Cabras, P. Dileo, B. Laterza et al., Diffuse Malignant Peritoneal Mesothelioma: Failure Analysis Following Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy (HIPEC), Annals of Surgical Oncology, vol.14, issue.suppl, pp.463-72, 2008.
DOI : 10.1245/s10434-008-0219-1

T. Chua, T. Yan, and D. Morris, Outcomes of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal mesothelioma: The Australian experience, Journal of Surgical Oncology, vol.27, issue.2, pp.109-122, 2009.
DOI : 10.1002/jso.21177

C. Ihemelandu, L. Bijelic, and P. Sugarbaker, Iterative Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Recurrent or Progressive Diffuse Malignant Peritoneal Mesothelioma: Clinicopathologic Characteristics and Survival Outcome, Annals of Surgical Oncology, vol.107, issue.6, pp.1680-1685, 2014.
DOI : 10.1245/s10434-014-3977-y

D. Magge, M. Zenati, F. Austin, A. Mavanur, M. Sathaiah et al., Malignant Peritoneal Mesothelioma: Prognostic Factors and Oncologic Outcome Analysis, Annals of Surgical Oncology, vol.19, issue.4, pp.1159-65, 2014.
DOI : 10.1245/s10434-013-3358-y

D. Trump and D. Smith, Systemic therapies Manual of clinical oncology, pp.202-225, 1994.

D. Daydé, D. Ternant, M. Ohresser, S. Lerondel, S. Pesnel et al., Tumor burden influences exposure and response to rituximab: pharmacokinetic-pharmacodynamic modeling using a syngeneic bioluminescent murine model expressing human CD20, Blood, vol.113, issue.16, pp.3765-72, 2009.
DOI : 10.1182/blood-2008-08-175125

Y. Lin, H. Kao, J. Li, J. Hwang, Y. Tseng et al., Tumor Burden Talks in Cancer Treatment with PEGylated Liposomal Drugs, PLoS ONE, vol.438, issue.1, p.63078, 2013.
DOI : 10.1371/journal.pone.0063078.t003

N. Vogelzang, J. Rusthoven, J. Symanowski, C. Denham, E. Kaukel et al., Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural Mesothelioma, Journal of Clinical Oncology, vol.21, issue.14, pp.2636-2680, 2003.
DOI : 10.1200/JCO.2003.11.136

R. Kelly, E. Sharon, and R. Hassan, Chemotherapy and targeted therapies for unresectable malignant mesothelioma, Lung Cancer, vol.73, issue.3, pp.256-63, 2011.
DOI : 10.1016/j.lungcan.2011.04.014

J. Brahmer, S. Tykodi, L. Chow, W. Hwu, S. Topalian et al., Safety and Activity of Anti???PD-L1 Antibody in Patients with Advanced Cancer, New England Journal of Medicine, vol.366, issue.26, pp.2455-65, 2012.
DOI : 10.1056/NEJMoa1200694

J. Ioannidis, A. Haidich, M. Pappa, N. Pantazis, S. Kokori et al., Comparison of Evidence of Treatment Effects in Randomized and Nonrandomized Studies, JAMA, vol.286, issue.7, pp.821-851, 2001.
DOI : 10.1001/jama.286.7.821

G. Lonjon, I. Boutron, L. Trinquart, N. Ahmad, F. Aim et al., Comparison of Treatment Effect Estimates From Prospective Nonrandomized Studies With Propensity Score Analysis and Randomized Controlled Trials of Surgical Procedures, Annals of Surgery, vol.259, issue.1, pp.18-25, 2014.
DOI : 10.1097/SLA.0000000000000256